BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34492588)

  • 21. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
    Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
    PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
    Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
    Hua S; Gu M; Wang Y; Ban D; Ji H
    Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. m
    Wang A; Sun Y; Wang X; Yan Z; Wang D; Zeng L; Lu Q
    Aging (Albany NY); 2023 Aug; 15(16):8444-8457. PubMed ID: 37647025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
    Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
    Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
    Masugi Y; Nishihara R; Yang J; Mima K; da Silva A; Shi Y; Inamura K; Cao Y; Song M; Nowak JA; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig S; Fuchs CS; Qian ZR; Ogino S
    Gut; 2017 Aug; 66(8):1463-1473. PubMed ID: 27196573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
    Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
    Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer
    Tian J; Wang W; Zhu J; Zhuang Y; Qi C; Cai Z; Yan W; Lu W; Shang A
    J Immunol Res; 2022; 2022():4012920. PubMed ID: 35497876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
    Chen YL; Wang GX; Lin BA; Huang JS
    Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer.
    Yang Q; Huang G; Li L; Li E; Xu L
    J Immunol Res; 2021; 2021():5964752. PubMed ID: 33628843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.